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Relation between Anemia and Vulnerable Coronary Plaque 
Components in Patients with Acute Coronary Syndrome: Virtual 
Histology-Intravascular Ultrasound Analysis
The aim of the present study was to evaluate the plaque components and the predictors of 
thin-cap fibroatheroma (TCFA) in anemic patients with acute coronary syndrome using 
virtual histology-intravascular ultrasound (VH-IVUS). Anemia was defined according to 
criteria of the World Health Organization, (i.e., hemoglobin levels  < 13 g/dL in men and 
< 12 g/dL in women) and we compared VH-IVUS findings between anemia group (171 
patients, 260 lesions) and non-anemia group (569 patients, 881 lesions). Anemia group 
had greater % necrotic core (NC) volume (21% ± 9% vs 19% ± 9%, P = 0.001) compared 
with non-anemia group. Hemoglobin level correlated negatively with absolute NC volume 
(r = -0.235, P < 0.001) and %NC volume (r = -0.209, P < 0.001). Independent predictors 
of TCFA by multivariate analysis were diabetes mellitus (odds ratio [OR], 2.213; 95% 
confidence interval [CI], 1.403-3.612, P = 0.006), high-sensitivity C-reactive protein (OR, 
1.143; 95% CI, 1.058-1.304, P = 0.012), microalbuminuria (albumin levels of 30 to 300 
mg/g of creatinine) (OR, 2.124; 95% CI, 1.041-3.214, P = 0.018), and anemia (OR: 2.112; 
95% CI 1.022-3.208, P = 0.028). VH-IVUS analysis demonstrates that anemia at the time 
of clinical presentation is associated with vulnerable plaque component in patients with 
acute coronary syndrome. 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
The incidence of anemia is relatively high in patients with coro-
nary artery disease. Anemia is a cardiovascular risk factor in the 
general population (1), and was found to be associated with a 
significantly higher rate of cardiovascular events in patients with 
acute coronary syndrome (ACS) (2-4), heart failure (4, 5), in pa-
tients undergoing percutaneous coronary intervention (6, 7), 
and in patients undergoing coronary artery bypass graft surgery 
(8). Therefore, there is a possibility that anemia is associated 
with both development/progression of coronary atherosclero-
sis and coronary plaque vulnerability.
  However, no study has examined the relation between ane-
mia at the time of clinical presentation and coronary plaque 
characteristics in patients with ACS. Therefore, the purpose of 
the present study was to attempt to compare grey-scale and vir-
tual histology-intravascular ultrasound (VH-IVUS) findings be-
tween patients with anemia and those without anemia at the 
time of clinical presentation of ACS.
MATERIALS AND METHODS
Patient population
We reviewed 740 consecutive patients with ACS who underwent 
grey-scale and VH-IVUS between January 2007 and September  
2010. Anemia was defined according to criteria of the World 
Health Organization (i.e., hemoglobin levels  < 13 g/dL in men 
and  < 12 g/dL in women) (9). We compared baseline charac-
teristics, coronary angiographic findings, and grey-scale and VH-
IVUS findings between anemia group (171 patients, 260 lesions) 
and non-anemia group (569 patients, 881 lesions). The presence 
of unstable angina was determined by chest pain within the pre-
ceding 72 hr with or without ST–T-wave changes or positive car-
diac biochemical markers (creatine kinase-myocardial band or 
cardiac specific troponin-I). The presence of ST-segment eleva-
tion myocardial infarction was determined by  > 30 min of con-
tinuous chest pain, a new ST-segment elevation  ≥ 2 mm on at 
least 2 contiguous electrocardiographic leads, and creatine ki-
nase-myocardial band (MB) or cardiac-specific troponin I above Hong YJ, et al.  •  Anemia and Plaque Components
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2 times of normal. The presence of non–ST-segment elevation 
myocardial infarction was diagnosed by chest pain and positive 
cardiac biochemical markers (creatine kinase-myocardial band 
or cardiac-specific troponin I) without new ST-segment eleva-
tion. Hypercholesterolemia was diagnosed in patients who re-
ceived lipid-lowering medication or had a history of a low-den-
sity lipoprotein level  > 130 mg/dL. Heart failure was defined as 
the presence of previous clinical signs and symptoms of pulmo-
nary venous congestion or previous evidence of systolic dysfunc-
tion (left ventricular ejection fraction  < 50%) on echocardio-
gram. We excluded patients with subacute or late stent throm-
bosis, totally occluded lesions, restenosis after stenting, coro-
nary artery bypass graft failure, severe heart failure or cardio-
genic shock, important systemic disease, or serum creatinine 
> 2.5 mg/dL, and patients in whom adequate IVUS images could 
not be obtained. Hospital records of all patients were reviewed 
to obtain clinical demographics and medical history. 
Laboratory analysis 
Peripheral blood samples were obtained before coronary angi-
ography using direct venipuncture. The blood samples were 
centrifuged, and serum was removed and stored at -70°C until 
the assay could be performed. Absolute creatine kinase-MB 
levels were determined by radioimmunoassay (Dade Behring 
Inc., Miami, FL, USA). Cardiac-specific troponin I levels were 
measured by a paramagnetic particle, chemiluminescent im-
munoenzymatic assay (Beckman, Coulter Inc., Fullerton, CA, 
USA). The serum levels of total cholesterol, triglyceride, low-den-
sity lipoprotein cholesterol, and high-density lipoprotein cho-
lesterol were measured by standard enzymatic methods. High-
sensitivity C-reactive protein was analyzed turbidimetrically with 
sheep antibodies against human C-reactive protein; this has 
been validated against the Dade-Behring method (10). A ran-
dom morning urine specimen was obtained. Urine creatinine 
and albumin were measured on a Kodak Ektachem 700 Ana-
lyzer and Beckman Array 360 CE protein Analyzer (Beckman 
Instruments, Fullerton, CA, USA), respectively. Patients with al-
bumin levels of 30 to 300 mg/g of creatinine were defined as 
having microalbuminuria (11).
 
Coronary angiographic findings
Coronary angiogram was analyzed with validated QCA system 
(Phillips H5000 or Allura DCI program, Philips Medical Systems, 
the Netherlands). With the outer diameter of the contrast-filled 
catheter as the calibration standard, the reference diameter and 
minimal lumen diameter were measured in diastolic frames 
from orthogonal projections. Perfusion was evaluated accord-
ing to thrombolysis in myocardial infarction (TIMI) criteria (12).
Gray-scale and VH-IVUS imaging and analysis 
All IVUS examinations were performed after intracoronary ad-
ministration of 300 µg nitroglycerin using a commercially avail-
able IVUS system (Volcano Corp, Rancho Cordova, CA, USA). 
The IVUS catheter was advanced distal to the target lesion, and 
imaging was performed retrograde to the aorto-ostial junction 
at an automatic pullback speed of 0.5 mm/sec. In case of total 
occlusion, we opened the occluded artery by thrombus aspira-
tion or balloon angioplasty using small balloon. 
  Gray-scale IVUS and VH-IVUS data were analyzed by 2 inde-
pendent observers. The levels of reproducibility for external 
elastic membrane (EEM), lumen, and plaque plus media (P&M) 
cross-sectional areas (CSAs) using the Spearman rank-order 
correlation coefficients were 0.96, 0.97, and 0.97, respectively. 
Similarly, for plaque components by VH-IVUS, reproducibility 
for the fibrous (FT), fibro-fatty (FF), dense calcium (DC), and 
necrotic core (NC) volume measurements using the Spearman 
rank-order correlation coefficients were 0.93, 0.94, 0.93, and 
0.93, respectively. 
  Quantitative volumetric gray-scale and VH-IVUS analyses 
were performed across the entire lesion segment, and cross-sec-
tional analyses were performed at the minimum lumen sites and 
at the largest NC sites. Conventional quantitative volumetric 
gray-scale IVUS analysis was performed according to the Amer-
ican College of Cardiology Clinical Expert Consensus Document 
on Standards for Acquisition, Measurement and Reporting of 
Intravascular Ultrasound Studies (13). Measurements were made 
by every 1-mm interval for the region of interest, which was de-
fined as the segment between distal to proximal reference sites 
that were the most normal looking within 5 mm proximal and 
distal to the lesion. References were the single slices with the 
largest lumen and smallest plaque CSAs within 10 mm proxi-
mally and distally. Hypoechoic plaque was less bright than the 
adventitia, hyperechoic noncalcified plaque was as bright as or 
brighter than the adventitia without acoustic shadowing, and 
hyperechoic calcified plaque was brighter than the adventitia 
with acoustic shadowing. When there was no dominant plaque 
composition, the plaque was classified as mixed. 
  Volumetric data were generated by the software using Simp-
son’s method. EEM and lumen CSAs were measured. P&M CSA 
was calculated as EEM minus lumen CSA; and plaque burden 
was calculated as P&M divided by EEM CSA. VH-IVUS analysis 
classified the color-coded tissue into four major components: 
green (FT); yellow-green (FF); white (DC); and red (NC) (14-17). 
VH-IVUS analysis was reported as a percentage of plaque area 
or volume. We defined thin-cap fibroatheroma (TCFA) as a NC 
≥ 10% of plaque area in at least 3 consecutive frames without 
overlying fibrous tissue in the presence of  ≥ 40% plaque bur-
den (15).
Statistical analysis 
The statistical Package for Social Sciences (SPSS) for Windows, 
version 15.0 (Chicago, IL, USA) was used for all analyses. Con-Hong YJ, et al.  •  Anemia and Plaque Components
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tinuous variables were presented as the mean ± SD; compari-
sons were conducted by Student’s t-test or nonparametric Wil-
coxon test if normality assumption was violated. Discrete vari-
ables were presented as percentages and relative frequencies; 
comparisons were conducted by chi-square statistics or Fisher’s 
exact test as appropriate. Pearson’s correlation coefficient was 
used to evaluate the associations between baseline hemoglobin 
level and each plaque components. Multivariate analysis was 
performed to determine the independent predictors of TCFA. A 
P value < 0.05 was considered statistically significant. 
Ethics statement
The study protocol was reviewed and approved by the institu-
tional review board of Chonnam National University Hospital 
(1-2009-07-082). Informed consent was waived by the board.
RESULTS
Baseline characteristics and laboratory findings
The baseline characteristics are summarized in Table 1. Patients 
with anemia were significantly older, were more females, and 
were more diabetics and were less smokers, and had more his-
tory of previous coronary intervention compared with those 
without anemia. Glucose level, high-sensitivity C-reactive pro-
tein, and urinary albumin-to-creatinine ratio were significantly 
higher in patients with anemia compared with those without 
anemia. Anemia group had significantly lower low-density lipo-
protein cholesterol and apolipoprotein B levels compared with 
non-anemia group.
Coronary angiographic findings
Angiographic findings are summarized in Table 2. Type B2/C 
lesions and multi-vessel diseases were observed more frequent-
ly and lesion length was significantly longer in patients with ane-
mia compared with those without anemia. There were no sig-
nificant differences in the target vessel, TIMI flow grade, mini-
mal lumen diameter, and percent diameter stenosis between 
both groups.
Gray-scale IVUS results
Gray-scale IVUS results are summarized in Table 3. P&M CSAs 
were significantly greater at the proximal and distal references 
and at the minimum lumen site and at the largest NC site in pa-
tients with anemia compared with those without anemia. EEM 
Table 1. Baseline characteristics
Parameters
Anemia  
(n = 171)
No anemia  
(n = 569)
 P value
Age (yr) 67 ± 9   59 ± 11 < 0.001
Female gender, No. (%)    70 (41) 172 (30) 0.009
Clinical presentation, No. (%)  
   Unstable angina
   NSTEMI
   STEMI
  
 109 (64)
   28 (16)
   34 (20)
  
387 (68)
  80 (14)
102 (18)
0.3
 
 
Diabetes mellitus, No. (%)     68 (40) 137 (24) < 0.001
Hypertension, No. (%)   102 (60) 317 (56) 0.4
Smoking, No. (%)     39 (23) 200 (35) 0.001
Hypercholesterolemia, No. (%)   51 (30) 159 (28) 0.5
Family history of CAD, No. (%)     5 (3)  22 (4) 0.6
Prior MI, No. (%)     8 (5) 13 (2) 0.098
Previous PCI, No. (%)   23 (14) 20 (4) < 0.001
Ejection fraction (%) 57 ± 9 60 ± 8 0.2
Heart failure, No. (%)   17 (10) 45 (8) 0.3
Creatinine clearance 
   < 60 mL/min, No. (%)
  65 (38) 125 (22) < 0.001
Prior use of anti-platelet agent (%)      36 (14%)      97 (11%) 0.4
Prior use of statin (%)      73 (28%)    137 (24%) 0.4
White blood cells (10
3/µL)   7.1 ± 2.8   8.2 ± 3.0 < 0.001
Hemoglobin (g/dL) 11.5 ± 1.1 14.1 ± 1.2 < 0.001
Platelet count (10
3/µL) 222 ± 63 230 ± 70 0.2
Glucose (mg/dL) 153 ± 61 130 ± 38 < 0.001
Creatine kinase-MB (U/l)   16 ± 36   14 ± 42 0.6
Troponin-I (ng/mL)     5.3 ± 17.7     6.7 ± 35.1 0.6
Creatinine (mg/dL)   0.86 ± 0.40   0.99 ± 0.77 0.011
hs-CRP (mg/dL)   1.0 ± 3.1   0.4 ± 1.3 0.001
Urinary albumin-to-creatinine 
   ratio (mg/g)
    40 ± 129   14 ± 40 0.009
Total cholesterol (mg/dL) 164 ± 45 181 ± 41 < 0.001
Triglyceride (mg/dL)   96 ± 65 113 ± 71 < 0.001
LDL cholesterol (mg/dL) 101 ± 38 115 ± 37 < 0.001
HDL cholesterol (mg/dL)   47 ± 11   50 ± 19 0.015
Apolipoprotein A1 (mg/dL) 124 ± 22 130 ± 23 0.001
Apolipoprotein B (mg/dL)   83 ± 26   91 ± 27 < 0.001
Apolipoprotein B/A1 (mg/dL)   0.68 ± 0.27   0.93 ± 4.54 0.4
Lipoprotien (a) (mg/dL)   37 ± 37   28 ± 27 0.001
Data are No. (%), or mean ± SD. NSTEMI, non-ST segment elevation myocardial in-
farction; STEMI, ST segment elevation myocardial infarction; CAD, coronary artery 
disease; PCI, percutaneous coronary intervention; hs-CRP, high-sensitivity C-reactive 
protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Table 2. Coronary angiographic findings
Angiographic findings
Anemia  
(n = 260)
No anemia  
(n = 881)
P value
Target vessel, No. (%)  
   Left main
   Left anterior descending
   Left circumflex
   Right
 
13 (5)
143 (55)
  36 (14)
  68 (26)
 
44 (5)
485 (55)
159 (18)
193 (22)
0.4
ACC/AHA lesion type, No. (%)  
   A 
   B1 
   B2 
   C 
 
13 (5) 
  73 (28) 
122 (47) 
  52 (20) 
 
44 (5) 
414 (47) 
326 (37) 
  97 (11) 
0.014 
Multivessel disease, No. (%)   182 (70)  458 (52)  0.004 
TIMI flow grade, No. (%)  
   0 
   1 
   2 
   3 
 
23 (9) 
16 (6) 
  57 (22) 
164 (63) 
 
  89 (10) 
44 (5) 
175 (20) 
573 (65) 
0.5 
Lesion length (mm)  18 ± 10        14 ± 7  0.021 
Reference diameter (mm) 3.24 ± 0.47 3.21 ± 0.58 0.5
Minimal lumen diameter (mm) 1.20 ± 0.45 1.19 ± 0.60 0.8
Diameter stenosis (%) 63 ± 14 63 ± 16 0.9
Data are No. (%), or mean ± SD. ACC/AHA, American College of Cardiology/Ameri-
can Heart Association; TIMI, Thrombolysis In Myocardial Infarction.  Hong YJ, et al.  •  Anemia and Plaque Components
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CSAs were significantly greater at the distal references and at 
the largest NC site in patients with anemia compared with those 
without anemia. By volumetric analysis, anemia group had great-
er plaque volume and smaller lumen volume compared with 
non-anemia group.
VH-IVUS results 
At the minimum lumen site, absolute NC and DC areas were sig-
nificantly greater and %NC area was significantly greater in pa-
tients with anemia compared with those without anemia (Fig. 1). 
  At the largest NC site, absolute NC, DC, and FT areas were 
significantly greater, and %NC and DC areas were significantly 
greater in patients with anemia compared with those without 
anemia; conversely %FT area was significantly smaller in patients 
with anemia compared with those without anemia (Fig. 2). 
  Absolute NC and DC volumes were significantly greater, and 
absolute FT and FF volumes were significantly smaller in pa-
tients with anemia compared with those without anemia; and 
%NC and DC volumes were significantly greater; and %FT and 
FF volumes were significantly smaller in patients with anemia 
compared with those without anemia (Fig. 3). TCFA was ob-
served more frequently in patients with anemia compared with 
those without anemia (47% vs 35%, P < 0.001). 
Correlations between hemoglobin levels and plaque 
components 
Hemoglobin level correlated negatively with absolute NC vol-
ume (r = -0.235, P < 0.001), %NC volume (r = -0.209, P < 0.001), 
absolute DC volume (r = -0.211, P < 0.001), %DC volume (r =   
-0.193, P < 0.001), and correlated positively with absolute FT 
volume (r = 0.205, P = 0.001), %FT volume (r = 0.164, P = 0.001), 
absolute FF volume (r = 0.187, P = 0.001), and %FF volume (r =  
0.134, P < 0.001).
Independent predictors of TCFA 
Multivariate analysis was performed to identify independent 
predictors of TCFA. The following variables were tested (all with 
P < 0.2 in univariate analysis) including microalbuminuria, age, 
male gender, diabetes mellitus, hypertension, smoking, ejection 
fraction, anemia, high-sensitivity C-reactive protein, and mini-
mum lumen site plaque burden (all with P < 0.2 in univariable 
analysis). Independent predictors of TCFA included diabetes 
mellitus (odds ratio [OR], 2.213; 95% confidence interval [CI], 
1.403-3.612, P = 0.006), high-sensitivity C-reactive protein (OR, 
Table 3. Gray-scale intravascular ultrasound findings 
Findings
Anemia  
(n = 260)
No anemia  
(n = 881)
P value
Proximal reference
   EEM CSA (mm
2)
   Lumen CSA (mm
2)
   P&M CSA (mm
2)
   Plaque burden (%)
 
21.1 ± 6.7
12.6 ± 3.9
  8.5 ± 3.4
40 ± 8
 
20.7 ± 6.5
12.6 ± 2.8
  8.1 ± 3.2
39 ± 8
 
0.4
1.0
0.045
0.10
Minimum lumen site
   EEM CSA (mm
2)
   Lumen CSA (mm
2)
   P&M CSA (mm
2)
   Plaque burden (%)
 
18.8 ± 6.9
  6.0 ± 4.9
12.8 ± 5.1
  68 ± 14
 
18.1 ± 7.0
  6.0 ± 4.9
12.1 ± 4.9
  67 ± 15
 
0.13
0.9
0.032
0.5
Distal reference
   EEM CSA (mm
2)
   Lumen CSA (mm
2)
   P&M CSA (mm
2)
   Plaque burden (%)
 
18.8 ± 7.8
11.2 ± 3.9
  7.6 ± 4.1
39 ± 9
 
17.6 ± 7.8
10.8 ± 2.9
  6.8 ± 3.7
38 ± 8
 
0.033
0.083
0.008
0.10
Largest necrotic core site
   EEM CSA (mm
2)
   Lumen CSA (mm
2)
   P&M CSA (mm
2)
   Plaque burden (%)
 
20.6 ± 6.8
  7.8 ± 4.8
12.8 ± 5.2
  62 ± 14
 
19.5 ± 7.0
  7.6 ± 5.0
11.9 ± 5.1
  61 ± 14
 
0.033
0.6
0.030
0.8
Plaque morphology, No. (%)  
   Hypoechoic
   Hyperechoic, noncalcified
   Hyperechoic, calcified
   Mixed
 
117 (45)
  65 (25)
  47 (18)
  31 (12)
 
432 (49)
203 (23)
141 (16)
106 (12)
0.3
Volumetric analysis
   EEM volume (µL)
   Lumen volume (µL)
   Plaque volume (µL)
 
  280 ± 208
123 ± 87
  157 ± 127
 
  293 ± 361
  138 ± 117
  146 ± 137
 
0.17
0.022
0.043
Data are No. (%), or mean ± SD. EEM, external elastic membrane; CSA, cross-sec-
tional area; P&M, plaque plus media.
m
m
2
%
	 FT	 FF	 DC	 NC 	 FT	 FF	 DC	 NC
10
8
6
4
2
0
100
80
60
40
20
0
4
59
0.8 12 0.6 10 1.2 18
P	=	0.16
P	=	0.10
P	=	0.4
P	=	0.2
P	=	0.001
P	=	0.10
P	=	0.001
P	=	0.033
4.2
58
0.8 11 0.8 11 1.5 20
Minimum	lumen	site	absolute	plaque	area Minimum	lumen	site	relative	plaque	area
A B
Fig. 1. Plaque component analysis according to the presence or absence of anemia at the minimum lumen sites. Results are displayed for (A) absolute and (B) relative quantifi-
cations. FT, fibrotic; FF, fibro-fatty; DC, dense calcium; NC, necrotic core.
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1.143; 95% CI, 1.058-1.304, P = 0.012), microalbuminuria (albu-
min levels of 30 to 300 mg/g of creatinine) (OR, 2.124; 95% CI, 
1.041-3.214, P = 0.018), and anemia (OR, 2.112; 95% CI, 1.022-
3.208, P = 0.028).
DISCUSSION
The present VH-IVUS study demonstrated that 1) patients with 
anemia had greater NC and DC components and had more 
TCFAs compared with those without anemia, 2) baseline he-
moglobin level correlated negatively with NC and DC compo-
nents and correlated positively with FT and FF components, 
and 3) anemia was the independent predictor of TCFA in pa-
tients with ACS.
  Previous pathological studies have demonstrated that plaque 
rupture and subsequent thrombus formation is the most impor-
tant mechanism leading to an ACS (18, 19). Plaque components 
may play a pivotal role in the plaque disruption and thrombosis 
that leads to acute coronary events (20-22). Several VH-IVUS 
studies have reported that ACS patients had more NC-contain-
ing lesions compared with stable angina patients (15, 23). In the 
present study which enrolled patients with ACS, mean %NC 
volume was about 21% and the proportion of patients with %NC 
volume  > 20% was 53% of total patient population. Lesions with 
a large lipid core may have a higher risk for disruption than scle-
rotic plaques (24-26).
  Anemia is present in 15%-30% of patients with ACS, and it 
adversely affects the outcomes of ACS (2-4). Anemia has the 
potential to worsen the myocardial ischemic insult in ACS, both 
by decreasing the oxygen delivery to myocardium downstream 
of coronary stenosis and by increasing myocardial oxygen de-
mand through necessitating a higher stroke volume and heart 
rate to maintain adequate systemic oxygen delivery. The com-
bination of these processes may explain the pathophysiology of 
poor clinical outcomes in patients with ACS with lower hemo-
globin levels (2).
  The significance of anemia in ACS has been focused on the 
significance of hemorrhagic complications during the treatment 
of ACS and on the prognostic significance of transfusions (27-
29). No special attention has been devoted to the significance 
of anemia on its’ relation to plaque characteristics in patients 
with ACS. In the present study, patients with anemia had great-
er plaque burden compared with those without anemia, and 
NC components were significantly greater, and TCFAs were ob-
m
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served more frequently in patients with anemia compared with 
those without anemia, and anemia was the independent pre-
dictor of TCFA. There are several postulated mechanisms that 
low hemoglobin levels are related to the development and pro-
gression of atherosclerosis and to the plaque vulnerability in 
patients with ACS. Anemia may worsen arterial intima-media 
thickening, and activate the sympathetic nervous system and 
renin-angiotensin-aldosterone axis, and impair oxygen carry-
ing capacity and enhance levels of proinflammatory cytokines 
(30). Especially, anemia is associated with underlying inflam-
matory processes, so it is likely that patients with low hemoglo-
bin levels might be more at risk of developing atherosclerosis 
and may affect the plaque vulnerability in patients with ACS.
  There are several limitations to be mentioned. First, the anal-
yses were retrospective and are subject to limitations inherent 
in this type of clinical investigation. Second, gray-scale and VH-
IVUS imaging were performed at the discretion of the individu-
al operators, leading to potential selection bias. Third, we did 
not attempt to differentiate between atherosclerotic plaque and 
thrombus because IVUS could not determine the presence of 
thrombus. This may obscure the identification of TCFA. Fourth, 
heavily calcified plaques may induce an artifact regarding the 
codification of plaques by VH-IVUS resulting in an increase in 
NC content. This remains a potential limitation of the present 
VH study. Fifth, nature of anemia (acute or chronic, causes of 
anemia, etc) was not evaluated in the present study. Sixth, pa-
tients with anemia had more comorbidities (more elderly pa-
tients, more females, more diabetics, higher high-sensitivity C-
reactive protein, higher microalbuminuria, and so on) compared 
with those without anemia in the present study. Therefore, these 
more comorbidities may affect more vulnerable plaque charac-
teristics in patients with anemia. However, in the present study, 
anemia itself was an independent predictor of large NC-contain-
ing plaque by multivariate analysis. So, it may be important to 
recognize hemoglobin as an indicator of plaque vulnerability.
  In conclusion, anemia at the time of clinical presentation of 
ACS is associated with large plaque burden and vulnerable plaque 
characteristics in patients with ACS. Therefore, intensive medi-
cal therapies like high-dose statins may be needed for plaque 
regression and stabilization in patients with ACS who accom-
panies with anemia. 
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